AQST Aquestive Therapeutics Inc

$AQST Just only Libervant Blockbuster Seizure Drug, AQST is targeting in US only about 450,000,000 +Million Dollar Annual Sales. LOL this is going to be a huge. CANADA, UK also coming in for Libervant. Its going ro explode in Sales. $ETON Eton is not a small company, it's Multi Billion dollar Marke cap company. AQST with ETON libervant partnerships going ro be huge soon. NOW with Sidley represents. MEGA EXPLOSION coming in for AQSTnand ETON for Libervant December and January US FDA full approval and January 9th Libervant full Market exclusitivity rights with AQST worldwide. This AQST stock could explode anytime.. $TSLA $NVDA $MU Now add the Annaphylm in March. EXPLOSION..

$AQST Key Takeaways for Anaphylm If we look at how the FDA handled neffy, they approved the drug roughly two months ahead of the standard 6 month PDUFA deadline. ARS Pharma officially resubmitted their application to the FDA on April 2, 2024. As a Class 2 resubmission, it was assigned a standard 6-month clock, placing its official PDUFA goal action date in early October 2024. The FDA ultimately approved neffy on August 9, 2024 which was two months earlier than its PUDFA date. I believe the same will happen with Anaphylm.

$AQST AQST holding very well considering the NASDAQ down almost 600pts. Today's news will price in once the market settles a bit. I am thinking AQST's deal with ETON is at least good enough to push us over $5 in the near term. We will see.

$AQST The primary major events capable of triggering a short squeeze: Early FDA Approval of Anaphylm would be the Ultimate Catalyst. The absolute premier trigger would be an outright FDA approval on or before the March 16, 2027 PDUFA date just like what happened with Neffy when they received FDA approval 60 days before the FDA PDUFA Date on their second go around after their CRL. . Why would it trigger a squeeze? Short sellers are heavily anchored to the January 2026 Complete Response Letter rejection. A clean approval removes the ultimate regulatory risk, validates the product as the first and only oral rescue film for anaphylaxis, and catches bears completely off-guard. How about a Strategic Commercial Partnership or Buyout. If Aquestive signs a major global marketing and distribution partnership with a Big Pharma peer, or is acquired entirely shorts are toast. Only time will tell.

$AQST I hope I didn't over reach. Just bought 250 calls ( 25,000 shares) for May 2027 at a strike of 4 dollars. I'm now fully committed to this stock 🙏

$AQST Long time holder and still bullish here. Two things I think need mentioning for long term holders: 1. The Eton agreement is more lucrative than it appears. $10M up front, $10M with first commercial sale, $2.5M for Libervant ages 6-11 approval. Plus $35M for milestones met (you can bet these are achievable), mid-teens royalties, and manufacturing exclusivity for a product that not along ago AQST said was a $100M opportunity at peak sales! 2. On the downside not much has been threaded here about the loss of Dr. Steve Wargacki in 2025, who developed the buccal administrative genius of prodrugs. I sincerely believe that AQST 108 has been stunted by his death, especially when there is no more discussion of Alopecia Arrieta but rather Atopic Dermatitis for 108, a very crowded market without delivery obstacles! In the end if a buyout occurs within a year of Anaphylm’s launch, the price with be mid teens at best, not the $20-25 I was hoping for. Hope I’m wrong!

$AQST Trust your research, stay focused on the fundamentals, and don't let the market's daily ups and downs dictate your decisions. Volatility is part of investing, and temporary setbacks don't necessarily change a company's long-term potential. Be patient, remain disciplined, and have the conviction to stand by your analysis—while staying open to new information. Successful investing isn't about predicting every market move; it's about making informed decisions and having the patience to let them play out.

$AQST With PDUFA update, this will go up 6+ in no time. Algos just need clarity for movement. That BULL FLAG is so evident. 15%+ day coming soon

$AQST If you think the FDA will wait until until March 16th to approve Anaphylm, you’re crazy. They will approve this way before then IMHO. Best case December, 2026, worst case January, 2027. It was FDA rules that dictated a Class 2 but the FDA will approve Anaphylm as though it was a class 1 just as they did with Neffy.

$AQST $ENVX Can someone repost this so can see it? He has me blocked. We had a falling out, and now I’m hearing he’s calling me a 'short scammer' and trying to get other people to block me. That accusation is false. Judge me by my posts, not his personal grudge. Questioning a company doesn’t make me a scammer. , I will be reporting these posts to Stocktwits and asking them to review your account for targeted harassment. Blocking me doesn’t give you a free pass to spread lies about me. Keep it about the stock and stop the personal attacks.

$AQST Modeling the scenario where Anaphyl gets FDA approval, transitions to OTC and has a strong commercial adoption (Libervant and 108 not included) (ChatGPT): Potential AQST share prices for successful OTC conversion ($38-40), strong OTC ($69-72), exceptional growth ($92-96, but $2B growth considering world-wide is $115+). As we already know, the global epinephrine market is expected to reach $5.5 to $6.1B by 2030-2034. Also, The company's current presentation identifies, not including present licensing agrrements: • Anaphylm: >$1B potential annual revenue • Libervant: >$100M • AQST-108: >$500M potential annual revenue

$AQST I think we all kind of knew that Libervant was going to be nice little cash flow source of AQST and this deal gives a little money up front and just under $50M in milestones and a mid teens royalty, so not too bad. Let Eton do all the heavy lifting and we get some cash flow but, this also clears the table for AQST to concentrate on Anaphylm. If the market was expecting a bigger deal than this, I am not sure what they were hoping for? More money upfront? Ok but, then you get a smaller royalty deal. The royalty deal is where the money will come from long term. I rather have the mid teens royalty deal than a bunch of cash up front. I think that is what AQST was thinking as well. Sorry the market was disappointed with this deal but, not sure what they were expecting here.

$AQST the closing low in august was $3.60. Let's see if that provides some support. Class 2 is exactly what the company forecasted so fundamentally nothing has changed (at least what is available to the public). IMO this selling is not shareholders bailing on the stock. Feels more like a big short with an agenda and plenty of capital.

$AQST Poor ae1213 - he bought one-trick pony SPRY at $15/share. He’s very broke and very very Bitter LOLOL

$AQST We have seen this before. I don’t like this drop but it was expected. We saw the short positions increase and they raided the stock today. It may be painful but increasing your positions over the next 30 days should reward you substantially.

$AQST Also, reminder that the FDA responded to Neffy, also a Class II, within 4 months, so a January response is not unrealistic.

$AQST The next scheduled earnings report (ER) for Aquestive Therapeutics (AQST) is estimated to take place between November 3 and November 6, 2026, with consensus tracking platforms leaning toward Wednesday, November 4, 2026.

$AQST w/in the next two weeks we should hear on AQST resubmission and whether Class 1 or 2. Expecting SPRY's playbook, meaning Class 2 but early decision. AQST's CRL was lot simpler.

$AQST Additional of new board member seems to be a signal that the company is going to go it alone post approval. Otherwise, why add him? Either way, it’s a winner.

$AQST Its not that retail wants to sell. Most of them are margin called right now. They have no choice but to sell. And this niche sector is where retail lives because the stocks are cheap and most have no idea how this sector works. Unfortunately, for them, many will lose everything. Those are the shares you are buying right now. Their pain will become your wealth.